Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlycoMark, Inc.
New York City, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
GlycoMark test is an FDA-cleared, CE-marked diagnostic for monitoring glucose control in diabetes patients, assessing postprandial glucose and drug adherence (e.g., SGLT-2 inhibitors). Recent studies validate its use in prediabetes and COVID-19 severity.[3][5]
- Therapeutic areas
- Endocrinology
- Modalities
- Diagnostic test
- Industry
- Metabolite Diagnostics
02
Partnerships
Precision Diabetes, Inc.Premier Medical Laboratory ServicesDxGen Corp.Patia Europe
Beyond the preview
Go deeper on GlycoMark, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlycoMark, Inc..